| Date | Title | Description |
| 06.05.2024 | T2 Biosystems Announces the Conversion of an Additional $15 Million of CRG Term Loan into Equity | - |
| 12.03.2024 | T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirement | - |
| 20.02.2024 | T2 Biosystems Strikes Deal with CRG for Debt-to-Equity Conversion | T2 Biosystems, a pioneer in rapid sepsis detection, shakes hands with CRG to swap $15 million in debt for equity. This move, pending shareholder approval, aims to bolster T2 Biosystems' financial standing. The company's CEO, John Sperzel, e... |
| 15.02.2024 | T2 Biosystems Announces Agreement with CRG for the Conversion of $15 Million of CRG Term Loan into Equity | LEXINGTON, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the entrance into a definitive agreement to ... |
| 15.02.2024 | T2 Biosystems Announces Agreement with CRG for the Conversion of $15 Million of CRG Term Loan into Equity | - |
| 24.12.2021 | Microbix Biosystems Inc. Receives $4.7 Million Order for Viral Transport Medium | Microbix Biosystems Inc. announces receipt of a follow-on order of CAD 4.7 million for its viral transport medium. DxTM is a sample-collection device that is essential for PCR-based testing for viruses that cause COVID-19 disease. This furt... |
| 07.10.2021 | T2 Biosystems : Development of a rapid, high sensitivity, direct from blood assay for identification of biothreat organisms | Development of a rapid, high sensitivity, direct from blood assay
for identification of biothreat organisms
Robert P. Shivers, Daniel Gamero, Kristen M. Roberts, Benjamin Chang, Alicyn R. Pearson, Judy Pacheco, Michael Min, Heather S. Lapp,... |
| 19.11.2020 | Rebus Biosystems, Inc. Announces $20 Million Series B Financing to Support Commercialization of Automated Spatial Omics Solution | |
| 22.09.2016 | T2 Biosystems Announces $40 Million Equity Investment by Partner Canon U.S.A. | LEXINGTON, Mass., Sept. 22, 2016 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a company developing innovative diagnostic products to improve patient health, today announced the purchase by Canon U.S.A., of approximately $40 million... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
| 19.08.2015 | Aisling Capital launching fourth, $400M life sciences fund | A document published on the Pennsylvania Public School Employees’ Retirement System indicated the fund has a $500 million hard cap, and that PSERS will commit $50 million.
This fund is actually smaller than its third, which launched in 2009... |
| 28.03.2013 | T2 Biosystems Completes $40M Series E |
LEXINGTON, MA, T2 Biosystems today announced the completion of a $40 million financing led by new investor Goldman Sachs.
>> Click here for more funding data on T2 Biosystems
>> To export T2 Biosystems funding data to PDF an... |
| 28.03.2013 | T2 Biosystems Completes $40M Financing | T2 Biosystems, a Lexington, MA-based clinical diagnostics company, completed a $40m financing.
The round was led by new investor Goldman Sachs, with participation from existing investors Flagship Ventures, Polaris Partners, Aisling Capital,... |
| 28.03.2013 | T2 Biosystems’ Series E round reaches $40M | T2 Biosystems, which is developing a diagnostic device that uses magnetic resonance technology to deliver nearly instant test results, said it raised a $40 million Series E round it plans to use for its T2Candida test for a common cause of ... |
| 28.03.2013 | Diagnostic to improve identification time for hospital acquired fungal infection gets Goldman Sachs backing | The test speeds up the detection time because it eliminates several steps from the current diagnostic process. It does not require optical detection, nor does it need biological samples to undergo purification, according to T2Biosystems’ we... |
| 22.03.2012 | Aligning Stakeholders in Emerging Med Tech Companies | So where do the wheels come off the bus? To answer this question, we sought the wisdom of John McDonough, CEO of T2 Biosystems and deep thinker on the topic of leadership alignment in VC-backed companies (John will show you his battle scars... |
| 10.08.2011 | T2 Biosystems Completes $23 Million Series D Financing | Lexington, MA, August 10, 2011 – T2 Biosystems® announced today that it has closed a $23 million series D financing. The round was led by new investor Aisling Capital, LLC, which was joined by existing investors Flagship Ventures, Polaris V... |
| 10.08.2011 | T2 Biosystems Closes $23M Series D Financing | T2 Biosystems, a Lexington, MA-based developer of products designed to detect molecular and immunoassay targets directly from unpurified clinical samples in hospitals, labs and physicians’ offices, has closed a $23m Series D financing.
The ... |
| 10.08.2011 | T2 Biosystems Completes $23M Series D |
Round was led by new investor Aisling Capital, which was joined by existing investors Flagship Ventures, Polaris Venture Partners, Flybridge Capital Partners, Physic Ventures, Partners Healthcare, Arcus Ventures, RA Capital, Camros Capita... |
| 07.04.2011 | T2 Biosystems device cuts bloodstream infection detection from 2 days to 2 hours | T2 Biosystems Inc. says its new blood test for the cause of a deadly blood pathogen could help make huge reductions in the mortality rate in people infected with the fungus Candida.
The Lexington, Mass.-based company’s new molecular diagnos... |
| 15.03.2011 | Johnson & Johnson names new DePuy Spine president | Namal Nawana is the new president of DePuy Spine, succeeding Gary Fischetti, who was named chairman of the DePuy group in January by its corporate parent, Johnson & Johnson (NYSE:JNJ).
Nawana, a 13-year vet at the New Brunswick, N.J.-ba... |
| 17.12.2010 | Sagentia chosen to drive development of T2 Biosystem's next generation medical diagnostic... | Sagentia chosen to drive development of T2 Biosystem's next generation medical diagnostic...
17-12-2010
International technology and product development company Sagentia has been hired by T2 Biosystems to work on the development of T2 Biosy... |
| 14.12.2010 | T2 Biosystems hires UK firm to help develop portable diagnostic system | The use of MR technology is faster, more reliable and may be less expensive for both molecular and immunodiagnostics applications because it requires less processing than optical-based diagnostic tool require, according to Sagentia.
T2‘s te... |
| 14.12.2010 | T2 signs Sagentia for nanotech diagnostics development | T2 Biosystems Inc. hired the Cambridge, U.K.-based consulting firm Sagentia to shepherd the development of its portable diagnostics system.
The Cambridge, Mass.-based start-up is developing nano- and miniaturized magnetic resonance-based te... |
| 25.05.2010 | T2 Biosystems raises $15 million Series C round | T2 Biosystems Inc. raised about $15 million in a Series C funding round it plans to use to bring its benchtop MRI-based diagnostic device to market.
The Cambridge, Mass.-based firm said Physic Ventures led the round, along with new backers ... |
| 17.10.2008 | T2 Biosystems brings in $10.8M for diagnostics | T2 Biosystems, a company working to develop new diagnostic methods, received $10.8 million in second-round financing from new investors In-Q-Tel (which also helps fund the CIA, incidentally) and Partners Healthcare, and existing investors F... |
| - | Aligning Stakeholders in Emerging Med Tech Companies | An emerging med tech company is like a family. There can be lots of drama. With the inevitable cycle of successes and setbacks in our highly regulated, unpredictable industry, the little corporate family can rally together or come apart at ... |
| - | Aisling Capital launching fourth, $400M life sciences fund | Aisling Capital, a life sciences-focused private equity firm, is raising $400 million for its fourth fund, with a hard cap of $500 million, Fortune reports.
The New York firm has a vast portfolio of healthcare and life sciences startups, wi... |
| - | T2 Biosystems hires UK firm to help develop portable diagnostic system | T2 Biosystems Inc. hired the Cambridge, U.K.-based consulting firm Sagentia to shepherd the development of its portable diagnostics system.
The Cambridge, Massachusetts-based start-up is developing nano- and miniaturized magnetic resonance-... |
| - | Diagnostic to improve identification time for hospital acquired fungal infection gets Goldman Sachs backing | A biotechnology company that’s developed a molecular diagnostic test platform to cut the time it takes to diagnose a hospital-acquired fungal infection called Candidemia from two days to three hours has secured fresh capital in a financing ... |